Medicare Enrolled
Dr. Nelly Awkar Lazo, M.D
Hematology & Oncology · Downey, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Awkar Lazo from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Awkar Lazo?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Awkar Lazo
Dr. Nelly Awkar Lazo is a hematology & oncology specialist in Downey, CA, with 15 years of NPI registration. Based on federal Medicare data, Dr. Awkar Lazo performed 161 Medicare services across 98 unique beneficiaries.
Between the years covered by Open Payments, Dr. Awkar Lazo received a total of $17,896 from 97 pharmaceutical and/or device companies across 841 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Awkar Lazo is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 15 years in practice
▲ 161 Medicare services
$17,896 industry payments
Medicare Practice Summary
Medicare Utilization ↗161
Medicare services
Bottom 15% in CA for hematology & oncology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
98
Unique beneficiaries
$81
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~11 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
66 | $99 | $272 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
49 | $71 | $191 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
19 | $45 | $120 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
16 | $70 | $201 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
11 | $99 | $217 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$17,896
Total received (2018-2024)
Avg $2,557/year across 7 years
Top 23% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
97
Companies
841
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$17,896 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,244
2023
$3,346
2022
$3,132
2021
$2,154
2020
$2,288
2019
$1,712
2018
$2,020
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$347
PFIZER INC.
$337
Incyte Corporation
$161
Celgene Corporation
$152
AstraZeneca Pharmaceuticals LP
$150
Merck Sharp & Dohme LLC
$114
ARRAY BIOPHARMA INC
$105
Takeda Pharmaceuticals U.S.A., Inc.
$104
Janssen Biotech, Inc.
$103
GlaxoSmithKline, LLC.
$100
Exelixis Inc.
$90
Sumitomo Pharma America, Inc.
$82
Bayer Healthcare Pharmaceuticals Inc.
$80
Eisai Inc.
$75
PUMA BIOTECHNOLOGY, INC.
$72
E.R. Squibb & Sons, L.L.C.
$66
Astellas Pharma US Inc
$64
Dendreon Pharmaceuticals LLC
$60
EMD Serono, Inc.
$60
Gilead Sciences, Inc.
$57
Daiichi Sankyo Inc.
$52
ABBVIE INC.
$52
GENZYME CORPORATION
$48
Regeneron Healthcare Solutions, Inc.
$47
Mirati Therapeutics, Inc.
$46
Karyopharm Therapeutics Inc.
$44
SOBI, INC
$40
Genentech USA, Inc.
$40
Immunocore Limited
$38
Ipsen Biopharmaceuticals, Inc
$37
Lilly USA, LLC
$36
Alexion Pharmaceuticals, Inc.
$34
Stemline Therapeutics Inc.
$33
PharmaEssentia USA Corporation
$32
Boehringer Ingelheim Pharmaceuticals, Inc.
$30
JAZZ PHARMACEUTICALS INC.
$27
Rigel Pharmaceuticals, Inc.
$25
Blueprint Medicines Corporation
$25
Aveo Pharmaceuticals, Inc.
$25
ADC Therapeutics America, Inc.
$24
TAIHO ONCOLOGY, INC.
$23
Agios Pharmaceuticals, Inc.
$23
Pharmacosmos Therapeutics Inc.
$22
Deciphera Pharmaceuticals Inc.
$21
BeiGene USA, Inc.
$21
Sirtex Medical Inc
$21
Top 3 companies account for 26.0% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,339
E.R. Squibb & Sons, L.L.C.
$957
PFIZER INC.
$918
Incyte Corporation
$907
AstraZeneca Pharmaceuticals LP
$821
Amgen Inc.
$596
Celgene Corporation
$595
Takeda Pharmaceuticals U.S.A., Inc.
$548
GlaxoSmithKline, LLC.
$512
Janssen Biotech, Inc.
$468
Genentech USA, Inc.
$444
Pharmacyclics LLC, An AbbVie Company
$437
Seagen Inc.
$415
Merck Sharp & Dohme LLC
$404
Merck Sharp & Dohme Corporation
$398
Exelixis Inc.
$384
GENZYME CORPORATION
$359
Gilead Sciences, Inc.
$304
Regeneron Healthcare Solutions, Inc.
$252
ARRAY BIOPHARMA INC
$250
Astellas Pharma US Inc
$242
Lilly USA, LLC
$235
Karyopharm Therapeutics Inc.
$234
Alexion Pharmaceuticals, Inc.
$234
Bayer HealthCare Pharmaceuticals Inc.
$213
Eisai Inc.
$208
Foundation Medicine, Inc.
$208
Daiichi Sankyo Inc.
$199
Sumitomo Pharma America, Inc.
$183
Puma Biotechnology, Inc.
$180
Taiho Oncology, Inc.
$148
EMD Serono, Inc.
$145
PUMA BIOTECHNOLOGY, INC.
$142
Intuitive Surgical, Inc.
$140
Blueprint Medicines Corporation
$135
Boehringer Ingelheim Pharmaceuticals, Inc.
$128
PharmaEssentia USA Corporation
$124
Ipsen Biopharmaceuticals, Inc
$124
Janssen Pharmaceuticals, Inc
$122
Octapharma USA, Inc.
$120
Kite Pharma, Inc.
$114
CTI BioPharma Corp.
$111
EUSA Pharma (US) LLC
$109
EISAI INC.
$106
Myovant Sciences Inc.
$105
AbbVie Inc.
$101
Stemline Therapeutics Inc.
$101
BeiGene USA, Inc.
$101
AbbVie, Inc.
$100
ABBVIE INC.
$93
Pharmacyclics LLC, an AbbVie Company
$89
Dendreon Pharmaceuticals LLC
$87
MorphoSys, US Inc.
$85
Bayer Healthcare Pharmaceuticals Inc.
$80
ADC Therapeutics America, Inc.
$78
Rigel Pharmaceuticals, Inc.
$78
Epizyme, Inc.,
$77
Mirati Therapeutics, Inc.
$73
Verastem, Inc.
$72
TAIHO ONCOLOGY, INC.
$70
Agios Pharmaceuticals, Inc.
$69
Emmaus Medical, Inc.
$62
SOBI, INC
$60
TESARO, Inc.
$59
MACROGENICS, INC.
$56
Sirtex Medical Inc
$56
Dova Pharmaceuticals
$55
ImmunoGen, Inc.
$54
Novocure Inc.
$50
Seattle Genetics, Inc.
$47
JAZZ PHARMACEUTICALS INC.
$46
Alnylam Pharmaceuticals Inc.
$44
Apellis Pharmaceuticals, Inc.
$41
Deciphera Pharmaceuticals Inc.
$41
Otsuka America Pharmaceutical, Inc.
$40
Immunocore Limited
$38
GE HEALTHCARE
$33
CSL Behring
$32
Adaptive Biotechnologies Corporation
$30
Janssen Scientific Affairs, LLC
$29
Spectrum Pharmaceuticals Inc.
$28
Secura Bio, Inc.
$25
Aveo Pharmaceuticals, Inc.
$25
Clovis Oncology, Inc.
$23
TG THERAPEUTICS, INC.
$23
Pharmacosmos Therapeutics Inc.
$22
Sobi, Inc
$22
SANOFI-AVENTIS U.S. LLC
$22
Acceleron Pharma, Inc.
$21
Helsinn Therapeutics (U.S.), Inc.
$20
APO-PHARMA USA, INC.
$20
Teva Pharmaceuticals USA, Inc.
$17
MEDIVATION FIELD SOLUTIONS LLC
$17
Array BioPharma Inc.
$17
CHIESI USA, INC.
$16
West Therapeutics Development, LLC
$15
Chiesi USA, Inc.
$13
Top 3 companies account for 18.0% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALOXI · ALUNBRIG · AYVAKIT · Abraxane · Afstyla · Alecensa · BAVENCIO · BENDEKA · BESREMI · BEXSERO · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · Braftovi · CABOMETYX · CALQUENCE · CHANTIX · COSELA · CYRAMZA · Cabometyx · Copiktra · DARZALEX · DOPTELET · Da Vinci Surgical System · Doptelet · ELIQUIS · ELITEK · ELREXFIO · ELZONRIS · EMPLICITI · ENHERTU · ENJAYMO · ERLEADA · EXKIVITY · Elahere · Empaveli · Endari · Enhertu · Erleada · FARYDAK · FERRIPROX · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · Folotyn · GAVRETO · GILOTRIF · GIVLAARI · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lazanda · Lenvima · Lonsurf · MARGENZA · MEKINIST · MONJUVI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONPATTRO · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · Optune · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · PYRUKYND · Padcev · Perjeta · Pomalyst · QINLOCK · REBLOZYL · RETEVMO · RYBREVANT · Reblozyl · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · Stivarga · Sylvant · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Trodelvy · UKONIQ · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VOTRIENT · Venclexta · Vitrakvi · Vonjo · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xofigo · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
452
Per 100K population
4.6
County median income
$87,760
Nearest hospital
PIH HEALTH DOWNEY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Awkar Lazo is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 15 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Awkar Lazo experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Awkar Lazo performed 66 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Awkar Lazo receive payments from pharmaceutical companies?
Yes. Dr. Awkar Lazo received a total of $17,896 from 97 companies across 841 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Awkar Lazo's costs compare to other hematology & oncology specialists in Downey?
Dr. Awkar Lazo's average Medicare payment per service is $81. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Awkar Lazo) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Downey
Browse hematology & oncology specialists in Downey ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology